Aug 11, 2026 earnings call — UNITY adoption and new product launches
Alcon reported second quarter sales of $2.8 billion, up 7% year-over-year.
Revenue $2.8B (est $2.7B) · EPS $0.84 (est $0.77)
Key quotes
"Demand for UNITY VCS remains robust, reflecting its versatility across both cataract and vitreoretinal procedures."
"Nearly all PanOptix accounts have been converted to PanOptix Pro with the platform now representing approximately 90% of PanOptix implants."
"TRYPTYR, our novel prescription treatment for dry eye disease, continues to gain momentum. Market access now includes nearly 2/3 of commercial lives and more than 20% of Medicare lives, including the recent addition of Humana Medicare Part D."
Analyst Q&A 13
equipment upgrades and IOL outlook
Q (Anthony Petrone · Mizuho Group): He asked what percent of the installed base will upgrade to UNITY VCS by year-end and what the device cycle looks like over 2–3 years. He also asked about IOL outlook tied to U.S. surgeon capacity and where that business could trend by 2027.
A: They are pleased with VCS demand and ASPs and say the funnel and unit movement are on track. For the 30,000-unit cycle they expect a bit more upfront adoption, then it will settle into steady replacement over time. On IOLs, PanOptix Pro adoption is strong and U.S. penetration is rising, helping long-term share stabilization.
"Of the 10 years, I divide it by 10, the 30,000, add a little more upfront, take a little way on the back end and then you're going to be kind of close to where we've always expected this to be." — David Endicott (CEO)
use of tariff refund and contact lens market
Q (Brett Fishbin · KeyBanc): He asked where the tariff refund will be reinvested in 2H and whether that step-up in investment is mostly one-time. He also asked if contact lens market growth is picking up toward the mid-single-digit range.
A: They will reinvest the tariff refund into areas tied to new product launches and some OTC ocular health opportunities; $40 million is relatively small versus total marketing and sales spend and will drive both near- and long-term revenue. On contact lenses, U.S. grew strongly (around 8%) while international was about 3%, giving a 6% global aggregate, which they view as healthy and on the high end of the typical range.
"$40 million is relatively small if you look at our total marketing and sales spend." — Timothy Stonesifer (CFO)
adjustable vs accommodating lenses and glaucoma plans
Q (Ryan Zimmerman · U.S. Bancorp): He asked whether the company has decided to pursue adjustable lenses only versus both adjustable and accommodating, and how that would affect the core franchise. He also asked about plans and views for surgical glaucoma.
A: They say they have not decided to do only one approach; accommodating plus tunable is seen as the long-term answer, but current tech (including PowerVision) has not yet achieved it. For glaucoma, Hydrus remains effective but reimbursement has changed dynamics; they are focusing on other parts of therapy like Voyager and SLT and remain opportunistic while stenting stays stable.
"I don't think we've made a decision to do one or the other." — David Endicott (CEO)
top-line guidance and IOL approvals timing
Q (Graham Doyle · UBS): He asked whether the 7% top-line guide is still plausible and when PanOptix Pro, Vivity Pro and TruPlus will be approved in U.S. and Europe.
A: Management left the 5%–7% range to investors to judge but reiterated new product launches and equipment comps as factors; they expect markets to grow around 3%–4%. PanOptix Pro is approved and launching in both U.S. and Europe; Vivity Pro is expected late this year or early next; TruPlus has CE Mark and they will manage its rollout carefully.
"PanOptix Pro is approved now in both U.S. and Europe." — David Endicott (CEO)
Valeda contribution and gross margin outlook
Q (Veronika Dubajova · Citi): She asked how much Valeda contributed to equipment growth and whether the 64% gross margin level (excluding licensing) is sustainable for the rest of the year.
A: They do not break out individual product sales but say Valeda contributed several points of growth and that UNITY CS and VCS are main equipment drivers; they see $100 million to $150 million peak for Valeda in 3–5 years. Gross margin was roughly 63% exit last year, about 64% in H1; the tariff refund is a onetime boost, Q3 margin may be higher and Q4 could dip toward a normalized rate.
"I would say that it contributed several points of growth in the quarter." — David Endicott (CEO)
contact lenses price vs volume and TRYPTYR trends
Q (David Saxon · Needham & Company): He asked how much of contact lens growth was price versus volume and how legacy versus core volumes are trending and about TRYPTYR's near-term trajectory.
A: They say price was about 4% of the roughly 5% contact lens growth in Q2, with strong U.S. share gains (about 1.5 share points) driven by promotion of key lenses. Legacy volume is declining while core growth and new reusable products broaden growth avenues. TRYPTYR will be in IQVIA July 10, they expect accurate data there and cite good share movement and refill rates indicating patient satisfaction.
"Price was about 4% in Q2 I think of the 5, it was significant." — David Endicott (CEO)
UNITY DX timing and Valeda outlook
Q (Larry Biegelsen · Wells Fargo): He asked for an update and timeline for UNITY DX and whether the Valeda peak sales view ($100–150m) should be revised upward and current run rate.
A: They had regulatory clearance but needed to rework manufacturability and durability; DX (pilot form) should be out later this year and revenue could start middle of next year as part of the UNITY/Adi ecosystem. They remain comfortable with the $100 million to $150 million peak range for Valeda and say uptake over ~9 months has been pleasing, but it is early to give more detail.
"Yes. We like the 100 to 150 range." — David Endicott (CEO)
end market health and cost savings program
Q (Steven Lichtman · William Blair): He asked about U.S. consumer sentiment for IOLs and contacts and whether the new cost efficiency program still targets $50m savings this year and $150m charges.
A: They see eye care demand largely independent of consumer confidence, with contact lenses and premium IOL penetration moving positively; U.S. penetration for AT-IOLs has room to grow. The cost program is on track: majority of actions taken, $100 million run rate with $50 million this year, and the $150 million charge expectation looks good.
"In fact, a majority of the actions have already been taken." — Timothy Stonesifer (CFO)
drivers of UNITY adoption and adjustable lens penetration
Q (Young Li · Jefferies): He asked what is driving UNITY adoption after a year — replacement versus efficiency benefits and whether UNITY accounts see more procedures. He also asked how Alcon could help increase LAL adjustable lens penetration in the U.S.
A: They say adoption has been driven by retina conversions, procedural speed and safety gains (20%–30% time savings), and the machine's usefulness across retina and cataract, making it appealing where ORs are shared. For LAL penetration questions they redirected to RxSight, pointing to Aziz there for better answers.
"I'd redirect that question to Aziz over at RxSight." — David Endicott (CEO)
UNITY backlog and EPS guide change
Q (Jeffrey Johnson · Baird): He asked whether the UNITY order book/backlog is bigger or smaller than six months ago and how to bridge the EPS guidance raise.
A: They describe demand as worked through initial pre-launch bolus and now as a relatively uniform, global opportunity with demo units and programs in market. The EPS guide movement is largely explained by the tariff refund and share buybacks and one-time items, and they feel core operating fundamentals and cost discipline remain intact.
"No. We feel pretty good about the investments in the underlying core operating margin." — Timothy Stonesifer (CFO)
implantables growth drivers and 2027 outlook
Q (Thomas Stephan · Stifel): He asked about expectations for 2H implantables growth, confidence that 2027 implantables can return to market growth with Vivity Pro, and why 2027 shouldn't decelerate after lapping UNITY.
A: They break implantables into market growth, penetration, and share. U.S. market growth has been below normal, but penetration is improving (U.S. up 180 basis points) which matters more economically. They expect continued product cadence (PanOptix Pro, Vivity Pro, monofocal plus, Valeda) to drive transitions and long-term growth, but share remains competitive so patience is advised.
"I think market growth in the U.S. has been below what we would normally expect." — David Endicott (CEO)
Systane multi-dose share and cataract market effects
Q (Susannah Ludwig · Bernstein): She asked what percent of Systane is multi-dose preservative-free and how sustainable Systane growth is. She also asked whether higher AT-IOL adoption affects procedure volumes.
A: They say about 15% of ocular health is the multi-dose preservative-free Systane product and Systane has been a double-digit grower; they expect more promotion in H2 and note international was already dominantly MDPF. On cataract volumes, AT-IOL adoption could affect time but economically often makes sense for practices; they are working on tools (UNITY DX and workflow digitization) to offset time and shift work to para-professionals.
"On ocular health, I think I'll just tell you that it's roughly 15% of ocular health is the MDPF." — David Endicott (CEO)
eye whitener product timing and differentiation
Q (Issie Kirby · Redburn): He asked for a timeline for the eye whitener product and what will differentiate it from competitors in sales.
A: They have not discussed it much but say approval should be late this year and it is positioned as a next-year product. They believe it will be better than the market leader but will disclose differentiation after approval and labeling are finalized.
"When we do have an approval, we'll look at the label." — David Endicott (CEO)